Letters to the Editor
Vol. 14 No. 1 (2022): Review Articles, Original Article, Scientific Letter, Case Reports Letter to the Editor
Sinopharm Vaccine, SARS-CoV-2 breakthrough infections and Hemoglobinopathies
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Received: April 22, 2022
Accepted: May 19, 2022
Accepted: May 19, 2022
809
Views
427
Downloads
186
HTML
Authors
Downloads
Download data is not yet available.
Citations
Karimi M, Zarei T, Haghpanah S, Azarkeivan A, Naderi M, Matin S, Bazrafshan A, Zahedi Z, Shirkavand A, Pishdad P, De Sanctis V. Efficacy and Safety of Sinopharm Vaccine for SARS-CoV-2 and breakthrough infections in Iranian Patients with Hemoglobinopathies: A Preliminary Report. Mediterr J Hematol Infect Dis. 2022 Mar 1;14(1):e2022026. doi: 10.4084/MJHID.2022.026. eCollection 2022.
Fucharoen S, Weatherall DJ. The hemoglobin E thalassemias. Cold Spring Harb Perspect Med. 2012 Aug 1;2(8):a011734.
Jantarabenjakul W, Chantasrisawad N, Puthanakit T, Wacharapluesadee S, Hirankarn N, Ruenjaiman V, Paitoonpong L, Suwanpimolkul G, Torvorapanit P, Pradit R, Sophonphan J, Putcharoen O. Short-term immune response after inactivated SARS-CoV-2 (CoronaVac®, Sinovac) and ChAdOx1 nCoV-19 (Vaxzevria®, Oxford-AstraZeneca) vaccinations in health care workers. Asian Pac J Allergy Immunol. 2021 Oct 31. doi: 10.12932/AP-250721-1197. Online ahead of print.
Kittikraisak W, Hunsawong T, Punjasamanvong S, Wongrapee T, Suttha P, Piyaraj P, Leepiyasakulchai C, Tanathitikorn C, Yoocharoen P, Jones AR, Mongkolsirichaikul D, Westercamp M, Azziz-Baumgartner E, Mott JA, Chottanapund S. Anti-SARS-CoV-2 IgG antibody levels among Thai healthcare providers receiving homologous and heterologous COVID-19 vaccination regimens. Influenza Other Respir Viruses. 2022 Feb 24. doi: 10.1111/irv.12975. Online ahead of print.
Supporting Agencies
noneHow to Cite
“Sinopharm Vaccine, SARS-CoV-2 breakthrough infections and Hemoglobinopathies” (2022) Mediterranean Journal of Hematology and Infectious Diseases, 14(1), p. e2022060. doi:10.4084/MJHID.2022.060.
Copyright (c) 2022 rujittika mungmunpuntipantip, viroj wiwanitkit
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
